The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
Sumatriptan injection is indicated in adults for the acute treatment of migraine
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Aims to achieve CDMO sales of US$ 400 million by 2028
Subscribe To Our Newsletter & Stay Updated
